Cardio-Metabolic and Renal Diseases

Areas of expertise

Testing new treatments in cardio-metabolic and kidney disease clinical trials is a challenge that requires the right investigators at the right sites. That is what we provide.

Patient recruitment and retention in this area is notoriously difficult. Julius Clinical has the leading scientific experts, experienced local investigators, and fine-tuned screening procedures to minimize this obstacle and provide the patient enrolment and retention your trial requires.

Meet our scientific leaders for cardio-metabolic and kidney disease trials

Prof. Dr. Diederick E. (Rick) Grobbee is Chief Scientific Officer at Julius Clinical and a professor of clinical epidemiology at the University Medical Centre (UMC) Utrecht, the Netherlands. His other current roles include chair of the circulatory health area at UMC Utrecht.

Meet our scientific leaders for cardio-metabolic and kidney disease trials

We collaborate with Prof. dr. Christophe Moreno, M.D., who is an expert in gastroenterology and hepatology and clinical director of the liver unit at CUB Hôpital Erasme, Brussels, Belgium. He is a valuable consultant to our MASH Clinical team.

Meet our scientific leaders for cardio-metabolic and kidney disease trials

Prof. Dr. Hiddo Lambers Heerspink is our Associated Scientific Leader for kidney disease clinical trials. Prof. Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of kidney and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He has successfully led and currently leads numerous clinical trials with new interventions to reduce diabetes related kidney and cardiovascular complications.

Highlighted trials

Our Scientific Networks

MASH Clinical

MASH Clinical is our global network of experienced clinicians and investigators with a special interest and deep experience in MASH (formerly known as NASH). The network is composed of endocrinologists, gastroenterologists, diabetologists, and internists.

Read more

Cardio Clinical

Cardio Clinical is a large global network of cardiologists and researchers who focus on developing novel therapies for cardiovascular diseases. Cardio Clinical comprises 1.000+ hospitals in 32 countries, providing sites and expertise around the world. The network has been involved in various large-scale randomised intervention trials on the prevention and treatment of cardiovascular disease.

Read more

Some highlighted studies

Spire

Phase III, Global

1505 Patients | 27 Countries | 485 Sites

Reducing occurrence of major cardiovascular events in high risk subjects.

CLEAR Outcomes

Phase III, Global

1667 Patients | 12 Countries | 224 Sites

Cardiovascular events in patients who are statin intolerant.

Advance

Phase III, Global

11,000 Patients | >20 Countries

The effects of routine antihypertensive therapy and glucose control therapy in patients with type II diabetes.

Convince

1360 Patients | 8 Countries | 62 Sites

Comparing high-dose Haemodiafiltration (HDF) versus conventional high-flux Haemodialysis (HD).

Alecardio

Phase III, Global

4072 Patients | 19 Countries | 436 Sites

Treatment on Cardiovascular Mortality a Morbidity in Subjects with type 2 Diabetes who experienced a recent Acute Coronary Syndrome.

Our expert cardio-metabolic team

We have an expert operational team for cardio-metabolic and kidney disease clinical trials with many years of focused experience. They are skilled at providing highly efficient, end-to-end CRO services that streamline studies and fulfil the expectations one should have for a therapeutically specialized CRO.

Rick grobbee
Manuel castro cabezas
Marco alings
Wiebe-Buitenwerf
Marcel bootsma
Elizabeth liano callahan
Vivian de jong

Related news & webinars

  • News
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Metabolic dysfunction associated steatotic liver disease and the heart

Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...

By: Sanne-Lotte van Barneveld
More webinars

Cardio-metabolic resources

Explore our cardio-metabolic capabilities, studies, and other resources.

Download

"*" indicates required fields

*
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

*
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn